Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR125543 fixed-dose trial in outpatients with major depressive disorder
2009-010339-42Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crinecerfont in major depressive disorder (MDD) (5 arms), sponsored by Sanofi. Primary endpoint: Change from baseline to Day 56 in 17-item Hamilton Depression Rating Scale total score. Started Oct 2009; status: completed.
02
Drugs
crinecerfont
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2009-010339-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010339-42.